Matches in DBpedia 2016-04 for { ?s ?p "Diabetes results from the loss or malfunction of the beta cells in the pancreas that make insulin. Autoimmunity has been the accepted explanation for type 1 diabetes (T1D) for 40 years, but clinical trials of immunotherapy have proved disappointing, and have not provided a means of prevention. The accelerator hypothesis proposes a different explanation for T1D, based on the tempo of beta cell loss and the environmental factors that drive it. The autoimmune diabetes Accelerator Prevention Trial (adAPT) is testing the accelerator hypothesis, by seeking to establish whether a drug which protects the beta cell metformin can slow the tempo of loss sufficiently to reduce the incidence of diabetes in children at risk. The trial is sponsored by the University of Exeter, conducted in Scotland by the Tayside Clinical Trials Unit and funded by JDRF. It will report finally in 2022."@en }
Showing triples 1 to 2 of
2
with 100 triples per page.
- Accelerator_Prevention_Trial_(adAPT) abstract "Diabetes results from the loss or malfunction of the beta cells in the pancreas that make insulin. Autoimmunity has been the accepted explanation for type 1 diabetes (T1D) for 40 years, but clinical trials of immunotherapy have proved disappointing, and have not provided a means of prevention. The accelerator hypothesis proposes a different explanation for T1D, based on the tempo of beta cell loss and the environmental factors that drive it. The autoimmune diabetes Accelerator Prevention Trial (adAPT) is testing the accelerator hypothesis, by seeking to establish whether a drug which protects the beta cell metformin can slow the tempo of loss sufficiently to reduce the incidence of diabetes in children at risk. The trial is sponsored by the University of Exeter, conducted in Scotland by the Tayside Clinical Trials Unit and funded by JDRF. It will report finally in 2022.".
- Q18350013 abstract "Diabetes results from the loss or malfunction of the beta cells in the pancreas that make insulin. Autoimmunity has been the accepted explanation for type 1 diabetes (T1D) for 40 years, but clinical trials of immunotherapy have proved disappointing, and have not provided a means of prevention. The accelerator hypothesis proposes a different explanation for T1D, based on the tempo of beta cell loss and the environmental factors that drive it. The autoimmune diabetes Accelerator Prevention Trial (adAPT) is testing the accelerator hypothesis, by seeking to establish whether a drug which protects the beta cell metformin can slow the tempo of loss sufficiently to reduce the incidence of diabetes in children at risk. The trial is sponsored by the University of Exeter, conducted in Scotland by the Tayside Clinical Trials Unit and funded by JDRF. It will report finally in 2022.".